linjc16/ctgov huggingface dataset:
A Study of c-Kit Mutation as MRD in Acute Myeloid Leukemia

Study Overview
=================
Brief Summary
-----------------
C-Kit is involved in an essential pathway of disease occurrence and is closely related to the poor prognosis of patients. However, the clinical significance of c-Kit mutation as molecular MRD monitoring is still unclear. What are the differences and advantages of using c-Kit mutation as MRD in prognostic assessment compared with other MRDs (MFC or RUNX1::RUNX1T1) widely used today? Existing data suggest that patients with one positive and one negative MRD results obtained by two different techniques have a higher risk of recurrence than patients with two negative MRD results but a lower risk of recurrence than patients with two positive MRD results. Therefore, can combining multiple MRD markers, including c-Kit mutations, overcome the shortcomings of a single molecular marker as MRD monitoring? Therefore, this project intends to confirm the clinical significance of quantitative detection of c-Kit mutation as MRD in acute myeloid leukemia.

Official Title
-----------------
Absolute Quantification of c-Kit Mutation as MRD in Acute Myeloid Leukemia: a Prospective Observational Study

Conditions
-----------------
C-KIT Mutation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who meet the diagnostic criteria(WHO 2016 criteria) of AML and have c-Kit D816 mutation. And receive treatment. Exclusion Criteria: Patients with other factors which were considered unsuitable to participate in the study by the investigators

Ages Eligible for Study
-----------------
Minimum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| MRD negative<br>c-Kit mutation tested negative | |
| MRD L1<br>MRD detection at low level-1：<0.001% | |
| MRD L2<br>MRD detection at low level-2：0.001%≤c-Kit MRD<0.01% | |
| MRD L3<br>detection at low level-3：0.01%≤c-Kit MRD<0.1% | |
| MRD positive<br>MRD positive：c-Kit MRD≥0.1% | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CIR | cumulative incidence of recurrence | Within 5 years after treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| OS | Overall Survival Rate | Within 5 years after treatment | 
| RFS | Relapse-free survival | Within 5 years after treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute myeloid leukemia, c-Kit mutation, MRD
A Close Examination of Patient Experiences in Glioblastoma Multiforme Clinical Research

Study Overview
=================
Brief Summary
-----------------
Clinical research can sometimes favor certain demographic groups. Additionally, there is limited research that delves into the factors that influence participation in clinical study, both positive and negative. The goal is to identify the obstacles and challenges that prevent participation in glioblastoma multiforme clinical study, as well as the reasons for withdrawal or discontinuation. Insights gained from this study will ultimately benefit those with glioblastoma multiforme who may be invited to participate in clinical trial in the years to come.

Official Title
-----------------
Glioblastoma Multiforme Patients in Clinical Trials: An Examination of Their Clinical Trial Experiences

Conditions
-----------------
Glioblastoma Multiforme

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of glioblastoma multiforme No prior treatment for glioblastoma multiforme Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: Female patients who are currently pregnant or nursing Enrolled in another research study Patients who are currently receiving any other investigational drug.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of patients who decide to enroll in a glioblastoma multiforme clinical study. |  | 3 months | 
| Number of glioblastoma multiforme study participants who remain in clinical trial until completion. |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
glioblastoma multiforme
Appraising Medical Trial Experiences of Ovarian Cancer Patients

Study Overview
=================
Brief Summary
-----------------
Historically, participation in clinical trials has been highly skewed towards specific demographic groups. However, research identifying which trial attributes impact participation, in either positive or negative ways, is limited. This study invites participants to record a wide range of data on their clinical trial experience, with the goal being to identify factors which persistently limit patients' ability to participate in, or complete, a trial in which they were initially interested. Data will be analyzed through a range of demographic lenses, in hopes of discovering patterns which might improve the experience of future ovarian cancer patients.

Official Title
-----------------
Analyzing Factors of Patient Involvement in Ovarian Cancer Clinical Trials

Conditions
-----------------
Ovarian Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed Patient has been diagnosed with ovarian cancer Subjects willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examination. Exclusion Criteria: Inability to perform regular electronic reporting Patient does not understand, sign, and return consent form Pregnant, breastfeeding or expecting to conceive within the projected duration of the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient decides to enroll in clinical trial |  | 3 Months | 
| Patient remains in clinical trial to completion |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ovarian cancer
COVID-19 Disease & Vaccine Survey in Africa

Study Overview
=================
Brief Summary
-----------------
The COVID-19 pandemic is a public health concern; for which the WHO recommends protective measures and vaccination. There is inadequate data on the impact of COVID-19 vaccination and control measures in Africa. This survey is collecting data about people's knowledge, attitude and compliance regarding COVID-19 disease and vaccines.

Detailed Description
-----------------
The coronavirus disease 2019 (COVID-19) pandemic remains a major public health concern. There is inadequate data on the epidemiology of COVID-19 in Africa. There are emerging COVID-19 variants with high transmissibility and morbidity. The World Health Organization (WHO) recommends protective measures and vaccination; for the control of COVID-19. There is inadequate data on the impact of COVID-19 vaccination and control measures in many nations in Africa. This study is a survey of specific urban populations in sub-Saharan Africa. The anonymized survey is collecting data about people's knowledge and attitude regarding COVID-19 disease or control measures. The survey is also collecting data about people's knowledge, attitude and compliance regarding COVID-19 vaccines. The study uses a validated questionnaire to collect data. The study aims to inform and improve COVID-19 management or control in Africa.

Official Title
-----------------
COVID-19 Disease & Vaccine Survey in Sub-Saharan Africa

Conditions
-----------------
Vaccine Hesitancy, COVID-19

Intervention / Treatment
-----------------
* Behavioral: Questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: urban population in Africa people in sub-Saharan Africa town Exclusion Criteria: rural population people outside sub-Saharan Africa

Ages Eligible for Study
-----------------
Minimum Age: 9 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Urban population Africa<br>Urban population in sub-Saharan Africa | Behavioral: Questionnaire<br>* Questionnaire survey for data collection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of people who know about COVID-19 prevention | Percentage of people who know about COVID-19 preventive measures | 6 months | 
| Percentage of people who received COVID-19 vaccination | Percentage of people who received COVID-19 vaccination, 1st and 2nd doses | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID-19
Relative Dose Intensity of Adjuvant Chemotherapy in Older Women With ER+ HER2- Breast Cancer.

Study Overview
=================
Brief Summary
-----------------
Localized breast cancers are defined as high-risk when they include lymph node involvement, Ki67 >30%, vascular emboli, low hormone receptor expression, or an unfavorable genomic signature result. Under these conditions, sequential adjuvant chemotherapy with taxanes and anthracyclines is recommended. Patients over 75 years of age receiving adjuvant chemotherapy are at greater risk of side-effects, which may necessitate dose reductions and a reduction in the intensity of chemotherapy. For curative adjuvant treatment, it is recommended to maintain a relative dose intensity (RDI) > 85%. A few publications have demonstrated the prognostic impact of a relative dose intensity < 85% for patients aged over 65. For several years now, the need for a specific assessment of elderly patients has been emphasized, prior to initiating oncological treatment (G8 score, onco-geriatric consultation). This study is a retrospective descriptive study of patients aged over 75 treated with adjuvant chemotherapy from 01/01/2012 to 01/01/2020 for RH+ HER2 - breast cancer in Franche Comté. Thus the investigators wish to identify patients at risk of receiving sub-optimal relative dose intensity, in order to guide early and targeted supportive care or geriatric co-management interventions.

Official Title
-----------------
Relative Dose Intensity of Adjuvant Chemotherapy in Older Women With ER+ HER2- Breast Cancer.

Conditions
-----------------
Breast Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women aged 75 or over Patient with localized RH+HER2- breast cancer Patient treated with adjuvant chemotherapy in Franche Comté between January 2012 and December 2019 Exclusion Criteria: Age < 75 Patient with metastatic breast cancer Patient who received neoadjuvant chemotherapy HER2+ breast cancer patient Breast cancer patient with missing or negative hormonal status Patient with localized recurrence of breast cancer with indication for new adjuvant therapy

Ages Eligible for Study
-----------------
Minimum Age: 75 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients receiving relative dose intensity (RDI) <85% |  | 01/01/2012 to 31/12/2019 |
The Technical and Operational Performance of the QuidelOrtho Savanna RVP4 Analyzer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is for the research team to become familiar with and evaluate the technical and operational performance of the QuidelOrtho Savanna RVP4 analyzer by testing 120 archived specimens that were previously tested at the Wisconsin State Laboratory of Hygiene (WSLH) by RT-PCR and multiplex respiratory pathogen panel within the last year.

Detailed Description
-----------------
To test the technical and operational performance of the QuidelOrtho Savanna RVP4 analyzer, the investigator proposes to test samples archived from the ORegon CHild Absenteeism due to Respiratory Disease Study (ORCHARDS) study (HSC 2013-1357), a study that had the goal to develop and implement a system for daily school-based monitoring of ILI (influenza-like illness) and CLI (COVID-like illness) student absenteeism in kindergarten (K) through grade 12 schools, and assess the system's usability for early detection of accelerated influenza, SARS-CoV-2 and other respiratory pathogen transmission in schools and surrounding communities. The deidentified paired (WSLH vs. Savanna RVP4) results will be used by QuidelOrtho Corporation to evaluate the technical and operational performance of the analyzer.

Official Title
-----------------
The Technical and Operational Performance of the QuidelOrtho Savanna RVP4 Analyzer

Conditions
-----------------
Respiratory Viral Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Previously collected specimens from the ORCHARDS study. Exclusion Criteria: Specimens not collected as part of the ORCHARDS study.

Ages Eligible for Study
-----------------
Minimum Age: 4 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ORCHARDS Study Specimens<br>Archived ORCHARDS study specimens | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Samples with Matching Results | There were a number of viruses detected in the ORCHARDS study [Ad, adenovirus; CoV, coronavirus; Flu, influenza virus; hMPV, human metapneumovirus; PIV, parainfluenza virus; R/E, rhinovirus/enterovirus; RSV, respiratory syncytial virus]. Reported here are the number of samples for which the Savanna RVP4 results match the WSLH results. | up to 6 months |
Comparison of Conventional Versus 3-D Printed Complete Denture Regarding Retention, Accuracy, Elctromyographic Activity and Patient Satisfaction.

Study Overview
=================
Brief Summary
-----------------
Analyzing and comparing the retention, accuracy, EMG and patient satisfaction of maxillary complete denture base fabricated by conventional and rapid prototyping techniques.

Official Title
-----------------
Electromyographic Activity, Accuracy, Patient Satisfaction and Retention of Conventional Versus 3-D Printed Maxillary Complete Denture: A Cross-over Randomized Controlled Trial

Conditions
-----------------
Edentulous Mouth

Intervention / Treatment
-----------------
* Other: 3D Printed Complete Dentures


Participation Criteria
=================
Eligibility Criteria
-----------------
Elligibility Criteria: Inclusion Criteria: Completely edentulous patients were selected to have their ridges covered with firm, thick and compressible mucosa All patients accepting prosthodontic treatment by an removable denture. Exclusion Criteria: TMJ disorder. Limited mouth opening or mandibular movement Muscle spasm or tenderness Mandibular deviation

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Conventional Complete Denture<br> | |
| Experimental: 3 D printed Complete Denture<br> | Other: 3D Printed Complete Dentures<br>* Denture bases printed from a pre-polymerized block via additive technique, using photon S desktop 3D printer* that relies on SLA technology and post cured by post curing unit.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of Retention | Retention was measured for both groups using the universal testing machine. Modification in each denture was made where two small metal tubes (3 mm diameters) were placed a few millimeters above the laterals in maxillary dentures by self-cure acrylic resin. The distance between the right tube and the geometric center was almost the same distance as between the left tube and the geometric center. The exact distance was checked using an orthodontic wire. | 3 months |
Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution

Study Overview
=================
Brief Summary
-----------------
This open-label, pilot study will evaluate the tolerance and change in the microbiome from the use of APR-TD011 ((RLF-TD011) wound cleansing spray for the treatment of CTCL skin lesions.

Official Title
-----------------
Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution

Conditions
-----------------
Cutaneous T Cell Lymphoma

Intervention / Treatment
-----------------
* Combination Product: APR-TD011 (RLF-TD011)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults with early-stage mycosis fungoides (stages IA-IB) At least two target lesions that have been present for at least 3 weeks and is at least 10 cm2 , so that at least one lesion may be allocated to each of the treatment regimes Target lesion with swab that is culture positive for staphylococcus aureus, but not to an extent that would require systemic antibiotics Agree to avoid washing or using a topical application at the target lesion starting the night before each scheduled study visit. Agree for the duration of study participation to avoid using dilute bleach or vinegar baths, or other antiseptic use, at the target lesion from screening throughout the study. Exclusion Criteria: Patients currently or recently (within past 4 weeks) on topical or systemic antibiotics adults unable to provide informed consent, (infants, children, teenagers, pregnant women, prisoners and other vulnerable populations.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CTCL participants<br>Visits will include screening, pre-treatment (week 0), weeks 4 and 8. | Combination Product: APR-TD011 (RLF-TD011)<br>* APR-TD011 (RLF-TD011) wound cleansing spray (drug/device combination product with a 510k clearance that is commercially marketed in the US for use by or on the order of a physician.<br>* Other names: Nexodyn AOS;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in microbiome species | Reduction of Staphylococcus aureus relative abundance between baseline and Week 4 | 4 weeks |
Titanium Prepared Platelet-rich Fibrin in Bone Regeneration in Lateral Window Maxillary Sinus Augmentation

Study Overview
=================
Brief Summary
-----------------
This trial aims to evaluate the effect of the sole use of T-PRF in bone formation process as applied in maxillary sinus floor elevation in comparison to traditional T-PRF/bone graft combination. This study is clinical trial that will include 18 patients seeking implant placement in upper posterior maxilla compromised with maxillary sinus pneumatization. Patients will be assigned into control and test groups. All the patients will undergo sinus lifting procedure through which a combination of xenograft and T-PRF was used in the control group whereas; sole T-PRF will be applied in the test group.

Official Title
-----------------
Evaluation of Titanium-prepared Platelet-rich Fibrin in Bone Regeneration in Lateral Window Maxillary Sinus Augmentation (Clinical Trial)

Conditions
-----------------
Sinus Lifting

Intervention / Treatment
-----------------
* Other: T-PRF alone
* Other: T-PRF/Xenograft


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Systemically in a healthy condition. Residual bone height is ≤5mm in the posterior maxilla as measured with CBCT. Non-smokers. Good oral hygiene as indicated by plaque and bleeding scores Exclusion Criteria: Medically compromised conditions will be excluded to avoid infections or any adverse reaction related to immunity suppression. Acute maxillary sinusitis. Patients administering any antibiotics or regular anti-inflammatory drugs.

Ages Eligible for Study
-----------------
Minimum Age: 18 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: T-PRF<br> | Other: T-PRF alone<br>* T-PRF is the material to be tested in this study as an alternative to classical bone graft<br>|
| Active Comparator: T-PRF/xenograft<br> | Other: T-PRF/Xenograft<br>* One part of T-PRF will be divided into minute pieces to be mixed with xenograft<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in pain level | measuring level of pain using visual analog scale (VAS) 0-10, where 0 reading indicates no pain and 10 reading reflects the most severe pain. | up to 2 weeks | 
| Change in bone volume | pre opertaive and post operative CBCT | up to 3 months | 
| Change in bone denisty | pre opertaive and post operative CBCT | up to 3 months | 
| Change in bone height | pre opertaive and post operative CBCT | up to 3 months |